Farmas USA

Ya está aquí el rebote, ahora a ver hasta donde llegamos durante esta semana, con idea de soltar y observar donde nos vuelven a tirar.

Igonber, por lo que he leido, en Bankinter te puedes poner largo "a credito" en valores USA del nasdaq 100 y DOW JONES 30. Pero no te puedes poner "corto" mas que en el Ibex35.

(Artículos)

ZIOP

Top Picks 2016: Ziopharm
http://www.moneyshow.com/articles.asp?aid=tptp072513-44145

CLDX

With Approval Likely, Celldex Needs To Expand Commercial Capabilities
http://seekingalpha.com/article/3816726-approval-likely-celldex-needs-expand-commercial-capabilities?auth_param=lfolr:1b9qpc2:c02ff45a4405bc5e6b35c51b0e3f3567&uprof=45&dr=1#alt3

INO

Inovio Pharmaceuticals Awarded Grant to Advance Needle-Free Vaccine Delivery Device

http://finance.yahoo.com/news/inovio-pharmaceuticals-awarded-grant-advance-130000558.html

TGTX

key corporate goals and objectives for 2016, which include the following:

Aggressively recruit into the GENUINE Phase 3 Clinical Trial of TG-1101 in combination with ibrutinib, which is now open in over 150 sites, with the goal of completing enrollment by YE16
Aggressively enroll into the UNITY-CLL combination Phase 3 clinical trial, of the Company’s proprietary combination of TG-1101 plus TGR-1202 (aka “TG-1303”)
Commence the UNITY- DLBCL Phase 2b/3 clinical trial
Initiate a Phase 1/2 clinical trial in Multiple Sclerosis (MS)
Commence a registration trial for iNHL in the 2H16
Present updated data on the Phase 1 and 2 clinical trials at major hematology/oncology conferences during 2016

“We enter 2016 with great optimism for the Company and our product candidates and the prospect of developing best-in-class treatment options for patients with B-cell malignancies. As each year passes we become more convinced that controlling key components of combination treatments and offering package pricing will be critical to ensuring all patients have access to the best care possible,” stated Michael S. Weiss, the Company’s Executive Chairman and Interim CEO. Mr. Weiss continued, “The objectives we have set for 2016 will mark a clear transformation for TG, with year-end 2016 seeing at least four ongoing registration directed clinical trials in oncology, commencement of our MS program, and most importantly, completion of enrollment into our first Phase 3 study, setting the stage for the possible launch of our first product in late 2017.”

http://finance.yahoo.com/news/tg-therapeutics-inc-sets-corporate-133422931.html

CTIX, digo yo que esta new debería ser positiva, ¿verdad?

Cellceutix Submits Briefing Book for Phase 2 Trial of p53 Targeting Drug for Ovarian Cancer

BEVERLY, MA--(Marketwired - January 19, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the briefing book with data collected during the Phase 1 clinical trial of Kevetrin for various advanced solid tumors has already been submitted to the U.S. Food and Drug Administration (FDA). This briefing book submission is in advance of the FDA meeting to discuss the planned Phase 2 clinical trial of Kevetrin for advanced ovarian cancer. Cellceutix is developing Kevetrin for ovarian cancer under an FDA Orphan Drug designation.
48 advanced-stage cancer patients were enrolled in the Phase 1 trial and received at least one dose of Kevetrin. 11 of the 48 patients in the trial had advanced ovarian cancer.
Kevetrin has a unique mechanism of action that enhances activity of p53, a key tumor suppressor protein, in both wild type and mutant p53-expressing tumors. In the Phase 1 trial, p53 activity is measured by increased expression of the protein p21, a downstream biomarker of p53, in peripheral blood lymphocytes. p21 increased by ≥ 10% in 48% of the 31 evaluable patients to date. Importantly, with respect to the planned Phase 2 trial for ovarian cancer, 8 of 11 subjects (73%) with advanced ovarian cancer had increases in p21 expression, indicative of activation of p53.
No evidence of adverse effects on liver, kidney or hematologic function related to Kevetrin was observed, regardless of dose. Therapeutic efficacy was not an endpoint in the Phase 1 trial. However, RECIST (Response Evaluation Criteria In Solid Tumors) criteria were used and several subjects had stable disease for several months during a Kevetrin treatment cycle of one dose per week for three weeks and then one week off. The longest enrolled subject has completed 15 cycles and remains enrolled in the trial.
In the planned Phase 2 ovarian cancer trial, Cellceutix intends to leverage the short half-life and strong pharmacokinetic profile of Kevetrin to change Kevetrin dosing from a single dose weekly to multiple doses weekly. The company expects that this will further increase p53 activity.
Ovarian cancer is a disease with a large unmet medical need and represents one of the fastest paths for approval for a clinically successful drug.
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

TGTX

Está claro que lo importante vendrá a finales de 2016. Si fuera un año alcista sería un momento cojonudo para cargar y esperar 11 meses. Como la situación es otra, a saber...

Por otra parte cuanta agresividad! "Aggressively recruit", "Aggressively enroll",... Ha desayunado fuerte la directiva!

ZGNX

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

http://finance.yahoo.com/news/zogenix-receives-fast-track-designation-130000016.html?soc_src=mediacontentstory&soc_trk=tw